Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failurePaul G. Richardson, Robert J. Soiffer, Marcie Riches et al.|Blood|2016Cited by 333
TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better OutcomesSung Won Choi, John E. Levine, David A. Hanauer et al.|Transplantation and Cellular Therapy|2012Cited by 62
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR OutcomesChristopher R. Flowers, Edmund K. Waller, Luciano J. Costa et al.|Transplantation and Cellular Therapy|2016Cited by 24
Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 TrialPaul G. Richardson, Robert J. Soiffer, Marcie Riches et al.|Blood|2015Cited by 1
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR OutcomesCésar O. Freytes, Ian W. Flinn, Isabelle Bence‐Bruckler et al.|DukeSpace (Duke University)|2020Cited by 0